Lactose EC Granules are pharmaceutical excipient granules based on lactose and presented in an enteric-coated or gastro-resistant granule format where specified by the finished product design. Lactose is an established pharmaceutical excipient used primarily as a diluent or filler in oral solid formulations. It may be supplied in different forms, including lactose monohydrate and anhydrous lactose, which are recognized as separate materials in the current USP-NF.
The EC designation refers to the finished granule system rather than to lactose itself. Lactose is not an enteric coating polymer. Enteric or gastro-resistant performance is achieved through an appropriate coating system or other validated formulation technology surrounding or incorporating the granules.
Lactose EC Granules are granulated lactose-based pharmaceutical excipient systems designed for applications where an enteric-protected or gastro-resistant granule format is required.
The underlying lactose can provide the desired excipient functionality, while the external enteric coating can be designed to protect the granules during the gastric stage and allow release under appropriate intestinal conditions.
Gastro-resistant granules are intended to resist gastric fluid and release their incorporated active material in intestinal fluid. The finished product therefore requires specific evaluation of coating integrity and release performance.
Lactose is a disaccharide composed of glucose and galactose and is widely used in pharmaceutical formulations. It can function as a diluent or filler and may contribute to the physical structure of an oral solid formulation.
USP-NF currently maintains separate monographs for Lactose Monohydrate and Anhydrous Lactose. Lactose Monohydrate is defined as the monohydrate of O-β-D-galactopyranosyl-(1→4)-α-D-glucopyranose, while Anhydrous Lactose is defined as β-lactose or a mixture of β- and α-lactose.
The exact lactose form should therefore be stated according to the actual product specification.
An enteric-coated granule system uses a gastro-resistant coating to control exposure of the underlying granules to the gastrointestinal environment.
The coating can provide protection during the acidic gastric stage and permit release after the granules reach an appropriate intestinal environment. The precise release behavior depends on the selected coating material, coating process, coating thickness, coating weight gain and formulation design.
For commercial Lactose EC Granules, the exact enteric polymer should be identified only when it is part of the approved product specification.
Because individual granules have a relatively high surface area, uniform coating coverage is important for consistent performance.
Finished Lactose EC Granules may therefore be evaluated for:
These are finished-product characteristics and should be controlled according to the actual product specification.
Gastro-resistant granules are designed to resist gastric conditions and subsequently release their incorporated material in intestinal fluid. Appropriate dissolution testing is therefore an important quality attribute for an EC granule system.
The exact dissolution conditions and acceptance criteria depend on the formulation and applicable standard. Therefore, values such as “NMT 10% release in acid stage” or “NLT 80% release in buffer” should not be entered unless those values are supported by the actual approved product specification.
The physical form of lactose is important when defining a commercial product.
Lactose Monohydrate contains one molecule of water of crystallization, while Anhydrous Lactose represents a different hydration state and is separately defined by USP-NF.
The FCC description identifies lactose as occurring as anhydrous lactose, lactose containing one molecule of water of hydration, or mixtures of the two forms depending on how it is prepared. FCC also describes lactose as soluble in water, very slightly soluble in alcohol and insoluble in chloroform and ether.
For an EC granule product, the finished appearance and physical characteristics can differ from the underlying lactose because of the coating and granulation processes.
Controlled granule characteristics can support consistent manufacturing and formulation performance.
Important characteristics can include:
The exact values should come from the product's certificate of analysis or approved specification.
Lactose EC Granules may be considered for pharmaceutical formulation development involving:
The final application depends on the complete formulation, coating technology and intended release profile.
Quality control for Lactose EC Granules should distinguish between the underlying lactose and the finished coated granule.
The lactose component may be evaluated for identity, moisture, lactose content, residue on ignition, optical rotation and other applicable pharmacopoeial characteristics.
The finished EC granules may additionally require evaluation of particle size, coating characteristics, acid resistance and dissolution performance.
USP-NF recognizes Lactose Monohydrate and Anhydrous Lactose as separate materials, so the appropriate compendial specification should correspond to the actual lactose form.
During development, Lactose EC Granules can be evaluated for compatibility with the coating system, granule size, coating uniformity, moisture, density and release performance.
The coating process should provide adequate and consistent coverage of the granules. Process parameters can influence coating thickness, surface characteristics and dissolution behavior.
For this reason, the finished EC granule specification should be based on validated product performance rather than generic coating values.
Lactose EC Granules can be evaluated for use in enteric-protected oral formulations, gastro-resistant multiparticulates, capsule-filled granules and other delayed-release pharmaceutical systems.
The exact release profile depends on the coating material, coating process, granule composition and formulation design.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 0.5% |